|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 26, 2017 ) BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) pipeline Target constitutes close to 19 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The latest report BDNFNT 3 Growth Factors Receptor-Pipeline Review H2 2017 outlays comprehensive information on the BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics complete with analysis by indications stage of development mechanism of action (MoA) route of administration (RoA) and molecule type.
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)-BDNF/NT-3 growth factors receptor is a protein encoded by the NTRK2 gene. It is involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival proliferation migration differentiation and synapse formation and plasticity. It acts as receptor for BDNF/brain-derived neurotrophic factor and NTF4/neurotrophin-4. It alternatively can also bind NTF3/neurotrophin-3 which is less efficient in activating the receptor but regulates neuron survival through NTRK2. Upon ligand-binding undergoes homodimerization autophosphorylation and activation. The molecules developed by companies in Phase III Phase I Preclinical and Discovery stages are 3 2 6 and 4 respectively. Similarly the universities portfolio in Preclinical stages comprises 4 molecules respectively. Report covers products from therapy areas Central Nervous System Oncology Cardiovascular Metabolic Disorders Ear Nose Throat Disorders Genetic Disorders and Ophthalmology which include indications Alzheimer's Disease Breast Cancer Solid Tumor Bile Duct Cancer (Cholangiocarcinoma) Huntington Disease Neuroendocrine Tumors Non-Small Cell Lung Cancer Pancreatic Cancer Parkinson's Disease Amyotrophic Lateral Sclerosis Brain Cancer Central Nervous System (CNS) Tumor Colorectal Cancer Melanoma Metastatic Colorectal Cancer Neuroblastoma Ovarian Cancer Papillary Thyroid Cancer Post-Traumatic Stress Disorder (PTSD) Rett Syndrome Salivary Gland Cancer Soft Tissue Sarcoma Stroke Acute Myelocytic Leukemia (AML Acute Myeloblastic Leukemia) Adrenocortical Carcinoma (Adrenal Cortex Cancer) Anaplastic Large Cell Lymphoma (ALCL) Anxiety Disorders Astrocytoma Biliary Tumor Bladder Cancer Charcot-Marie-Tooth Disease Colon Cancer Depression Diabetic Retinopathy Endometrial Cancer Epilepsy Epithelial Ovarian Cancer Fallopian Tube Cancer Fibrosarcoma Gastrointestinal Stromal Tumor (GIST) Glioblastoma Multiforme (GBM) Head And Neck Cancer Head And Neck Cancer Squamous Cell Carcinoma Hearing Disorders Hepatocellular Carcinoma Ischemic Optic Neuropathy Kidney Cancer (Renal Cell Cancer) Lung Cancer Major Depressive Disorder Metastatic Adenocarcinoma of The Pancreas Metastatic Brain Tumor Metastatic Melanoma Metastatic Renal Cell Carcinoma Multiple Sclerosis Neurology Non-Rhabdomyosarcoma Non-Small Cell Lung Carcinoma Obesity Ocular Melanoma Pain Peritoneal Cancer Pheochromocytoma Phobia Pontine Glioma Prostate Cancer Refractory Acute Myeloid Leukemia Refractory Multiple Myeloma Relapsed Acute Myeloid Leukemia Relapsed Multiple Myeloma Renal Cell Carcinoma Rhabdomyosarcoma Sarcomas Seizures Skin Cancer Tenosynovial Giant Cell Tumor Thyroid Cancer Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Traumatic Brain Injury Ureter Cancer Urethral Cancer and Wilms' Tumor (Nephroblastoma) .
Furthermore this report also reviews key players involved in BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources.
For more information about this report at http://www.reportsweb.com/bdnf-nt-3-growth-factors-receptor-pipeline-review-h2-2017
Report Scope
- The report provides a snapshot of the global therapeutic landscape for BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)
- The report reviews BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes product description descriptive MoA R&D brief licensing and collaboration details & other developmental activities
- The report reviews key players involved in BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA) route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001881480/sample
Reasons to buy
- Gain strategically significant competitor information analysis and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles
Addex Therapeutics Ltd
Array BioPharma Inc
AstraZeneca Plc
Boehringer Ingelheim GmbH
Chronos Therapeutics Ltd
Daiichi Sankyo Company Ltd
Exelixis Inc
Ignyta Inc
Loxo Oncology Inc
Plexxikon Inc
Takeda Pharmaceutical Company Ltd
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001881480/discount
List of Tables
Number of Products under Development by Stage of Development H2 2017
Number of Products under Development by Therapy Areas H2 2017
Number of Products under Development by Indications H2 2017
Number of Products under Development by Indications H2 2017 (Contd..1) H2 2017
Number of Products under Development by Indications H2 2017 (Contd..2) H2 2017
Number of Products under Development by Indications H2 2017 (Contd..3) H2 2017
Number of Products under Development by Indications H2 2017 (Contd..4) H2 2017
Number of Products under Development by Companies H2 2017
Products under Development by Companies H2 2017
Products under Development by Companies H2 2017 (Contd..1) H2 2017
Products under Development by Companies H2 2017 (Contd..2) H2 2017
Products under Development by Companies H2 2017 (Contd..3) H2 2017
Products under Development by Companies H2 2017 (Contd..4) H2 2017
Products under Development by Companies H2 2017 (Contd..5) H2 2017
Number of Products under Investigation by Universities/Institutes H2 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001881480/buy/3500
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
